Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
$7.04
-$0.17(-3.14%)
At close: 4:00 PM EST
$7.04
-$0.17(-3.14%)
Day’s Range― - ―
52-Week Range$3.21 - $8.05
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.56M
Market Cap
$1.79B
Enterprise Value$1.30B
Total Cash (Recent Filing)$242.71M
Total Debt (Recent Filing)$207.61M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding242,974,300
10 Day Avg. Volume5,463,458
30 Day Avg. Volume3,558,477
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)6.88
Price to Sales (P/S)3.57
P/FCF Ratio-26.03
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit3.67
Enterprise Value/Ebitda-45.68
Forecast
1Y Price Target
$14.33Price Target Upside103.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA solid cash position provides resources to fund pipeline programs and commercial investments, enabling continued execution without immediate financing risk.
Clinical DevelopmentInitiation of a Phase 3 study to evaluate Ibsrela in chronic idiopathic constipation could broaden the drug's approved use and substantially enlarge the addressable patient population if successful.
Commercial ExecutionExpansion of the commercial and field access teams has increased physician reach and improved prescription conversion, supporting sustained sales momentum for Ibsrela.
Bears Say
Near-term Revenue MomentumGuidance points to modest near-term revenue trends for XPHOZAH with limited acceleration, indicating constrained commercial momentum in the near term.
Regulatory And Execution RiskFuture growth relies partly on successful label expansion and clinical trial outcomes, introducing regulatory and execution risk that could delay or limit market opportunity.
Reimbursement And CoverageLoss of Medicare Part D coverage for XPHOZAH has reduced reimbursement and could constrain patient access and commercial performance.
Ardelyx News
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.21 and its highest was $8.05 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.79B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Mar 11, 2026 which is in 55 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Oct 30, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.058 by $0.058.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is 0.02.
How many shares outstanding does Ardelyx have?
Ardelyx has 242,974,300 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0 in its last earnings report, beating expectations of -$0.058. Following the earnings report the stock price went up 20.958%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (103.55% Upside)
$14.33 (103.55% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 58.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $800.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.72%
12-Months-Change
Fundamentals
Return on Equity
-36.18%
Trailing 12-Months
Asset Growth
32.16%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Ardelyx's strong financial performance, driven by significant growth in IBSRELA and XPHOZAH revenue. The introduction of a new compound, ARDX-10531, marks a positive step in pipeline development. However, challenges remain, particularly in achieving XPHOZAH's long-term revenue goals amidst market disruptions.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$14.33
▲(103.55% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.00% Insiders
20.14% Mutual Funds
0.04% Other Institutional Investors
62.94% Public Companies and
Individual Investors